Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia

Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia Clinical Trial

Official title: Phase II Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia

Status Completed

Clinical Trial Summary

The objective of this study is to examine the clinical dose range of ASP1585 based on the efficacy, safety, and feasibility of treatment in chronic kidney disease patients on hemodialysis with hyperphosphatemia.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia
• Hyperphosphatemia
• Kidney Diseases
• Renal Insufficiency, Chronic

• NCT number: NCT02753894
• Study type: Interventional
• Source: Astellas Pharma Inc
• Status: Completed
• Phase: Phase 2
• Start date: January 2008
• Completion date: June 2008